Oxford PharmaGenesis is pleased to announce an update to our publication policy, which provides clear ethical guidance on our involvement in publications. As of 1 January 2019, the policy includes a commitment to publishing our own research open access under the Creative Commons Attribution (CC BY) licence with no additional restrictions. This update will ensure that the company’s research can be read and reused by anyone who needs it, as part of our commitment to publishing medical research in an ethical, accurate and timely manner.
The introduction of this policy makes Oxford PharmaGenesis the first commercial research funder to require open access publication with a CC BY licence. A CC BY licence is widely viewed as the gold standard for open access, and so is mandated by funders such as the Bill and Melinda Gates Foundation and the Wellcome Trust. Chris Winchester, CEO, says, “We are proud to take this step towards a more open future for publications, which arose thanks to our involvement in Open Pharma.” Open Pharma is a multi-stakeholder project that aims to advance medical publishing by the pharmaceutical industry.